In a significant medical breakthrough, researchers from King’s College London have found that semaglutide, a drug commonly ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Sometimes, it makes sense to skip insurance and instead take advantage of a health savings account or flexible savings ...

Plainsboro: Novo Nordisk has announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application ...

Study participants were randomly assigned 2:1 to receive oral semaglutide 25mg (n=205) or placebo (n=102), as an adjunct to lifestyle intervention. The coprimary endpoints were the relative change in ...

The active ingredient in the popular weight loss drug Wegovy may help treat a type of fatty liver disease, according to a new study published Wednesday.

A decision is expected in the fourth quarter of 2025.

Novo Nordisk (NVO) stock in focus as oral Wegovy is accepted for FDA review for chronic weight management. Read more here.

Health Canada begins a priority review of semaglutide 2.4 mg, a weekly treatment by Novo Nordisk for MASH, a liver disease ...

Research revealed that medications widely used for diabetes and obesity may offer significant benefits for patients with ...

Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly ...

A study has found that Ozempic may reverse signs of a disease that contributes to 2,000,000 deaths per year. New research has ...